Exogene
Signal active
Organization
Contact Information
Overview
Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well as safe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
About
Industries
Biotechnology, Artificial Intelligence (AI), Life Science, Pharmaceutical
Founded
2019
Employees
1-10
Headquarters locations
Europe
Social
N/A
Profile Resume
Exogene headquartered in Europe, operates in the Biotechnology, Artificial Intelligence (AI), Life Science, Pharmaceutical sector. The company focuses on Biotechnology and has secured $67.4M in funding across 32 round(s). With a team of 1-10 employees, Exogene is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Exogene, raised $2.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
2
Investors
7
Lead Investors
0
Total Funding Amount
$2.1M
Details
1
Exogene has raised a total of $2.1M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2022 | Seed | 2.0M |
Investors
Exogene is funded by 12 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Nadav Rosenberg | - | FUNDING ROUND - Nadav Rosenberg | 2.0M |
| Jude Gomila | - | FUNDING ROUND - Jude Gomila | 2.0M |
| Exogene | - | FUNDING ROUND - Exogene | 2.0M |
| Unruly Capital | - | FUNDING ROUND - Unruly Capital | 2.0M |
Recent Activity
There is no recent news or activity for this profile.